Takeda Oncology (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Takeda Oncology" in English language version.

refsWebsite

Global rank English rank

2thepharmaletter.com

low place

2fiercebiotech.com

low place

8,828^th place

1nytimes.com

7^th place

1nature.com

234^th place

397^th place

1doi.org

2^nd place

1worldcat.org

5^th place

1nih.gov

4^th place

1bloomberg.com

99^th place

77^th place

1sec.gov

572^nd place

436^th place

1millennium.com

low place

1barrons.com

2,737^th place

1,700^th place

1bizjournals.com

407^th place

241^st place

1reuters.com

49^th place

47^th place

1fiercepharma.com

low place

8,921^st place

1fda.gov

447^th place

338^th place

1takeda.com

low place

barrons.com

online.barrons.com

Willoughby, Jack. "The New Science Behind Medical Investing". barrons. Retrieved 2024-01-08.

bizjournals.com

Seiffert, Don (8 October 2014). "Takeda will finally drop the name 'Millennium'". www.bizjournals.com. Retrieved 2024-01-19.

bloomberg.com

"Millennium Pharmaceuticals Acquires Cor Therapeutics". Bloomberg.com. Retrieved 2024-01-19.

doi.org

Dove, Alan (December 1999). "Millennium mergers bring pipeline". Nature Biotechnology. 17 (12): 1151. doi:10.1038/70687. ISSN 1546-1696. PMID 10585700.

fda.gov

accessdata.fda.gov

"FDA Approves VELCADE". FDA. Retrieved 2008-03-05.

fiercebiotech.com

"Schering-Plough buys Millennium's stake in heart drug". Fierce Biotech. 24 July 2005. Retrieved 19 January 2024.
Garde, Damian (8 December 2014). "Six years and $8.8B later, Takeda is ditching the Millennium name". Fierce Biotech. Retrieved 19 January 2024.

fiercepharma.com

Kansteiner, Fraiser (3 October 2023). "Takeda to pull lung cancer med Exkivity around the world after confirmatory trial flop". Fierce Pharma. Retrieved 8 January 2024.

millennium.com

investor.millennium.com

"VELCADE as Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone". Millennium Corporate Communications. Retrieved 2008-03-05.

nature.com

Dove, Alan (December 1999). "Millennium mergers bring pipeline". Nature Biotechnology. 17 (12): 1151. doi:10.1038/70687. ISSN 1546-1696. PMID 10585700.

nih.gov

pubmed.ncbi.nlm.nih.gov

Dove, Alan (December 1999). "Millennium mergers bring pipeline". Nature Biotechnology. 17 (12): 1151. doi:10.1038/70687. ISSN 1546-1696. PMID 10585700.

nytimes.com

Pollack, Andrew (2005-06-29). "Shift Seen Atop Takeda Oncology". New York Times. Retrieved 2008-02-23.

reuters.com

"Takeda announces voluntary withdrawal of lung cancer therapy". Reuters. 2 October 2023. Retrieved 8 January 2024.

sec.gov

"UNITED STATES SECURITIES AND EXCHANGE COMMISSION". www.sec.gov. Retrieved 2024-01-19.

takeda.com

"U.S. FDA Approves Takeda's NINLARO® (ixazomib), the First and Only Oral Proteasome Inhibitor to Treat Multiple Myeloma". Takeda. Retrieved 29 October 2017.

thepharmaletter.com

"Millennium to acquire Cambridge Discovery Chemistry for L35 million -". www.thepharmaletter.com. Retrieved 2024-01-19.
"Millennium Pharmaceuticals to acquire COR Therapeutics in $2 billion d". www.thepharmaletter.com. Retrieved 2024-01-19.

worldcat.org

search.worldcat.org

Dove, Alan (December 1999). "Millennium mergers bring pipeline". Nature Biotechnology. 17 (12): 1151. doi:10.1038/70687. ISSN 1546-1696. PMID 10585700.